Former U.S. Sen. Ben Sasse, who told the world in December 2025 that he was dying of stage 4 pancreatic cancer, now says an experimental oral drug has cut his tumor volume by 76 percent in four months, a result his doctors describe as a potential turning point for one of the deadliest cancers in medicine.
Sasse, 54, entered a clinical trial for daraxonrasib, a targeted therapy made by California-based Revolution Medicines, after his cancer spread to his liver and lungs and standard treatments offered little hope. He had been given three to four months to live.
In a recent interview with "60 Minutes," Fox News Digital reported, Sasse described the change in blunt terms:
"I have much, much less pain than I had four months ago when I was diagnosed, and I have a massive 76% reduction in tumor volume over the last four months."
That number, if it holds, would represent the kind of response pancreatic cancer patients almost never see. And it raises serious questions about how fast the federal approval process should move when a drug's trial data already shows it can double survival.
Sasse, the Republican who represented Nebraska from 2015 to 2023, went public with his diagnosis in December 2025. He did not soften the news. AP News reported that Sasse wrote plainly: "Last week I was diagnosed with metastasized, stage-four pancreatic cancer, and am gonna die."
He called advanced pancreatic cancer what it is, "a death sentence," as Just The News reported, but added that he was not giving up. "I'm not going down without a fight," Sasse wrote. He pointed to recent breakthroughs in immunotherapy and science as reasons for hope.
The announcement drew public support from Vice President JD Vance and Nebraska Republicans Deb Fischer and Don Bacon, the New York Post noted.
Sasse has also spoken candidly about the state of American politics from the vantage point of a man staring down a terminal illness, including sharp criticism of the Senate as a chamber of "blowhards" and a warning about deeper cultural decay.
Daraxonrasib targets a defective gene, RAS, that drives uncontrolled cell growth in the vast majority of pancreatic tumors. Sarbajit Mukherjee, M.D., chief of gastrointestinal medical oncology at Miami Cancer Institute, part of Baptist Health South Florida, explained the mechanism to Fox News Digital. Mukherjee was not involved in the trial and did not treat Sasse.
Mukherjee described the problem in direct terms:
"In pancreatic cancer, that switch is stuck in the 'on' position in the vast majority of tumors, constantly telling the cancer cells to grow and spread."
The drug, he said, is designed to bind to RAS in its active state and turn that signal down, slowing or shrinking the cancer. It is an oral therapy, a pill, not an infusion, which matters for patients already worn down by chemotherapy.
Fox News senior medical analyst Dr. Marc Siegel called daraxonrasib "the first-of-its-kind targeted therapy for pancreatic cancer." He added that the drug is in its final stages of clinical trials, where it has been shown to double the survival of patients previously treated for metastatic pancreatic cancer.
Revolution Medicines recently released data from a phase 3 trial of patients whose metastatic pancreatic cancer did not respond to standard chemotherapy. Patients on daraxonrasib lived a median of 13 months, compared to roughly six months for those who stayed on chemo.
That gap, more than double, is not a marginal gain. For a disease that has resisted meaningful progress for decades, it is the kind of result that demands attention from regulators.
Mukherjee did not mince words about the drug's significance. He told Fox News Digital that daraxonrasib "is the first targeted pill in this disease that truly feels like a step change rather than a small incremental improvement." He added:
"It opens the door to much more personalized strategies going forward. For a cancer where progress has been painfully slow, it could reshape how we care for patients with advanced disease."
He noted that current treatments for advanced pancreatic cancer are limited. Once standard chemotherapy stops working, "our options are limited and survival is usually measured in just a few more months," Mukherjee said. Ongoing trials are now asking whether daraxonrasib should be used as part of the very first treatment plan, not just as a last resort.
The health crises facing prominent Republican leaders have drawn growing public attention in recent months, including the hospitalization of Alabama Gov. Kay Ivey after a lung procedure.
Mukherjee was careful to set limits on the optimism. The drug is not yet FDA-approved. It is not a cure. Side effects include rash, diarrhea, mouth sores, and fatigue, and patients need regular blood tests and close follow-up.
Most sobering of all, Mukherjee acknowledged that cancer tends to adapt. "Over time, most cancers will eventually find ways to grow around the drug," he said.
But none of that erases the core fact: a man told he had three to four months to live saw his tumor volume drop by more than three-quarters in the same span of time. Sasse credits his faith for helping him outlast his original prognosis, and he credits the science for giving him a shot at more time.
Sasse himself has reflected on the strangeness of facing mortality at 54. "It's weird to be in your early 50s and get a terminal diagnosis, and people all of a sudden act like you're 93 or 94, and you have a lot of wisdom," he told "60 Minutes." He added: "I don't know that I have a lot of wisdom, but I have a lot of things that I think we should be reflecting on together."
The open questions are real. Sasse's reported tumor reduction has not been independently verified in public documents. The trial site and protocol details remain undisclosed. The FDA has not yet acted on the drug. And the disease's track record of outlasting treatments should temper any premature celebration.
But the data from Revolution Medicines' phase 3 trial, 13 months median survival versus six, speaks for itself. Dr. Siegel's characterization of the drug as a first-of-its-kind therapy carries weight when the alternative is watching patients run out of options in a matter of weeks.
Newsmax reported that Sasse, even while describing his diagnosis as terminal, emphasized his Christian faith, his family, and his refusal to quit. "One sub-part of God's grace is found in the jawdropping advances science has made the past few years in immunotherapy and more," he wrote.
The Senate that Sasse left behind has continued to generate its own share of drama, from the removal of a Republican senator at Trump's direction to ethics investigations involving unnamed lawmakers. Sasse, meanwhile, is fighting a different kind of battle, one where the stakes are measured not in votes but in months of life.
When a drug can double survival for one of the most lethal cancers known, the question isn't whether the FDA should approve it. The question is how fast.
